Drug Profile

JRF 104

Alternative Names: JRF-104

Latest Information Update: 22 Apr 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chengdu Jinrui Foundation Biotech
Class Antineoplastics
Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Acute myeloid leukaemia

Most Recent Events

22 Apr 2021 Discontinued - Preclinical for Acute myeloid leukaemia in China (PO) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)
22 Jun 2020 Preclinical trials in Acute myeloid leukaemia in China (PO) before June 2020
22 Jun 2020 Pharmacodynamics data from preclinical data in Acute myeloid leukaemia presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com